Latest News and Press Releases

ALLSCHWIL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. will announce the financial full-year 2006 results on Thursday, 22 February 2007 at 07.00 CET / 06.00 GMT / 01.00 a.m....

ALLSCHWIL, Switzerland, Feb. 5, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the proof-of-concept study in patients with primary insomnia receiving Actelion's Orexin-OX1/OX2...

ALLSCHWIL, Switzerland, Jan. 29, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the publication of both pre-clinical and placebo-controlled clinical data in the February edition of...

ALLSCHWIL, Switzerland, Jan. 9, 2007 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today that an indirect wholly-owned subsidiary, Curl Acquisition Subsidiary, Inc., has acquired a majority...

-- Significant reduction in pulmonary vascular resistance -- Strong trend towards improvement in exercise capacity -- Significant delay in time to clinical worsening -- Full data analysis...

ALLSCHWIL, Switzerland, Dec. 11, 2006 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that it has initiated a comprehensive Phase III program for Actelion-1, the first tissue targeting...

ALLSCHWIL, Switzerland, Dec. 8, 2006 (PRIME NEWSWIRE) -- Actelion Ltd. (SWX:ATLN) announced today that its indirect wholly owned subsidiary, Curl Acquisition Subsidiary, Inc., is commencing a cash...

-- Strengthening Actelion's strong role in advancing PAH therapy -- Strengthening the reach of Ventavis(r) in the United States -- Immediate positive effect expected on 2007 cash earnings --...

ALLSCHWIL, Switzerland, Oct. 19, 2006 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced its financial results for the first nine months of 2006. With total net revenues for the first nine months...

CHICAGO and ALLSCHWIL, Switzerland, Oct. 9, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today that the detailed analysis of the dose-finding study CONSCIOUS-1 (Clazosentan...